Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6%

INmune Bio, Inc. (NASDAQ:INMB) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 2,830,000 shares, a growth of 5.6% from the September 30th total of 2,680,000 shares. Based on an average daily trading volume, of 225,300 shares, the days-to-cover ratio is presently 12.6 days.

Insider Activity

In other INmune Bio news, CEO Raymond Joseph Tesi purchased 15,380 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, with a total value of $98,124.40. Following the acquisition, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other INmune Bio news, CEO Raymond Joseph Tesi purchased 15,380 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, with a total value of $98,124.40. Following the acquisition, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David J. Moss purchased 7,690 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, with a total value of $49,062.20. Following the completion of the acquisition, the chief financial officer now directly owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 33,070 shares of company stock valued at $200,087 in the last three months. 35.20% of the stock is currently owned by company insiders.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Advocates Investment Management lifted its position in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares in the last quarter. Fermata Advisors LLC lifted its position in shares of INmune Bio by 8.5% in the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock valued at $301,000 after acquiring an additional 2,689 shares in the last quarter. Westside Investment Management Inc. lifted its position in shares of INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after acquiring an additional 10,950 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of INmune Bio in the second quarter valued at $121,000. Finally, Bank of New York Mellon Corp lifted its position in shares of INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on INMB. Alliance Global Partners began coverage on INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock. Raymond James began coverage on INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Scotiabank began coverage on INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 target price on the stock.

INmune Bio Stock Performance

INMB opened at $5.95 on Thursday. INmune Bio has a one year low of $4.78 and a one year high of $14.74. The business’s fifty day moving average is $5.68 and its two-hundred day moving average is $7.84. The company has a market cap of $117.58 million, a price-to-earnings ratio of -2.89 and a beta of 1.85.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, analysts predict that INmune Bio will post -2.14 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.